DAPRIL

This brand name is authorized in Cyprus, Hong Kong SAR China, Malta, Singapore.

Active ingredients

The drug DAPRIL contains one active pharmaceutical ingredient (API):

1	Lisinopril UNII E7199S1YWR - LISINOPRIL
	Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion.
	Read more about Lisinopril

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DAPRIL Tablet	MPI, EU: SmPC	Υπουργείο Υγείας (CY)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09AA03	Lisinopril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	51881, 51882, 51883
MT	Medicines Authority	MA032/05401, MA032/05402, MA032/05403
SG	Health Sciences Authority	11994P, 11995P, 11996P